Although the use of PD-1/PD-L1 inhibitors plus chemotherapy has expanded treatment options for previously untreated PD-L1–positive advanced triple-negative breast cancer, there remains a need to improve outcomes. The phase III ASCENT-04/KEYNOTE-D19 study, presented at the 2025 ASCO Annual Meeting, evaluated the addition of the antibody-drug conjugate sacituzumab govitecan to pembrolizumab in patients with previously untreated, PD-L1–positive locally advanced unresectable or metastatic triple-negative breast cancer.
